Mantle Cell Lymphoma Articles | Page 2

Lenalidomide Plus Rituximab Safe and Effective as Initial Treatment for MCL
Lenalidomide (Revlimid) plus rituximab (Rituxan) is a feasible combination that is also safe and active, as initial and maintenance therapy for patients with mantle cell lymphoma.
Acalabrutinib MCL Approval Raises Sequencing Questions
Owen A. O'Connor, MD, PhD, discussed the utilization of acalabrutinib (Calquence), how it sequences with other approved therapies, and the promise for chimeric antigen receptor T-cell therapy in mantle cell lymphoma.
FDA Approves Acalabrutinib for Mantle Cell Lymphoma
The FDA has granted an accelerated approval to acalabrutinib as a treatment for adult patients with mantle cell lymphoma following at least 1 prior therapy.
Goy Shares Insight on Novel Therapies in MCL
Andre Goy, MD, discusses the excitement surrounding novel therapies on the horizon in MCL.
Rituximab Maintenance After ASCT Prolongs Survival in MCL
Maintenance rituximab (Rituxan) following autologous stem-cell transplantation improved survival in younger patients with mantle cell lymphoma, according to the LyMa trial.
Expert Covers Burgeoning Advancements in Follicular Lymphoma and MCL
Narendranath Epperla, MD, discusses the evolving treatment landscape for patients with follicular lymphoma and mantle cell lymphoma.
TP53 Predicts Poorer Survival in Mantle Cell Lymphoma
Multivariate analysis of the Nordic MCL2 and MCL3 trials showed that the presence of TP53 mutations predicted worse overall survival in younger patients with mantle cell lymphoma.
Observation After Diagnosis Viable Strategy for Some Patients With MCL
Some patients with mantle cell lymphoma can delay treatment without experiencing negative outcomes, according to findings from a population-based study.
Maintenance Rituximab Post-ASCT Associated With Improved OS in MCL
Patients who received maintenance therapy with rituximab (Rituxan) following autologous stem cell transplantation as treatment for mantle cell lymphoma had a survival advantage, according to results from a retrospective single-center study.
Ibrutinib Highly Active Against MCL in Pooled Analysis
In a pooled analysis, investigators determined that ibrutinib (Imbruvica) induced an objective response rate of 66% in patients with mantle cell lymphoma.
Publication Bottom Border
Border Publication